This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Wafaa El-Sadr, MD, MPH; Linnea Capps, MD, MPH

JAMA. 1992;267(7):954-957.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

RECENT efforts to extend clinical acquired immunodeficiency syndrome (AIDS) research trials to urban, poor, minority communities suggest that a new paradigm is required to make such efforts succeed. This new paradigm must reflect the special needs of these communities and should recognize historical distrust of clinical trials and the need for extensive educational and social support services.

The AIDS epidemic has focused attention on research and access to experimental therapy. The intensity of public debate may be new, but the problems are not. The proper sampling of a heterogeneous population has long been an important consideration in epidemiologic and clinical research, and it is well appreciated that race can affect disease severity and progression as well as response to drug therapy. A number of studies have shown differences between African Americans and whites in response to antihypertensive therapy.^1-3 These studies suggest that race is an important consideration when planning and . . . [Full Text PDF of this Article]

Author Affiliations
From the Division of Infectious Diseases, Department of Medicine, Harlem Hospital Center (Dr El-Sadr), and Columbia University College of Physicians and Surgeons (Dr Capps), New York, NY.

Footnotes
Reprint requests to Harlem Hospital Center, Division of Infectious Diseases, Room 3107, 506 Lenox Ave, New York, NY 10037 (Dr El-Sadr).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?